Gavin MacBeath
Overview
Explore the profile of Gavin MacBeath including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
3135
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang Q, Braun D, Clauser K, Ramesh V, Shirole N, Duke-Cohan J, et al.
Cell
. 2025 Mar;
PMID: 40023154
Clear cell renal cell carcinoma (ccRCC), despite having a low mutational burden, is considered immunogenic because it occasionally undergoes spontaneous regressions and often responds to immunotherapies. The signature lesion in...
2.
Meyer M, Mahr A, Brewer J, Daniel V, DellAringa J, Goldstone T, et al.
Nat Rev Drug Discov
. 2023 Nov;
23(1):1-2.
PMID: 38030734
No abstract available.
3.
Luoma A, Suo S, Wang Y, Gunasti L, Porter C, Nabilsi N, et al.
Cell
. 2022 Jul;
185(16):2918-2935.e29.
PMID: 35803260
Neoadjuvant immune checkpoint blockade has shown promising clinical activity. Here, we characterized early kinetics in tumor-infiltrating and circulating immune cells in oral cancer patients treated with neoadjuvant anti-PD-1 or anti-PD-1/CTLA-4...
4.
Oliveira G, Stromhaug K, Klaeger S, Kula T, Frederick D, Le P, et al.
Nature
. 2021 Jul;
596(7870):119-125.
PMID: 34290406
Interactions between T cell receptors (TCRs) and their cognate tumour antigens are central to antitumour immune responses; however, the relationship between phenotypic characteristics and TCR properties is not well elucidated....
5.
Denlinger C, Keedy V, Moyo V, MacBeath G, Shapiro G
Invest New Drugs
. 2021 Jul;
39(6):1604-1612.
PMID: 34250553
Background Overactivation of human epidermal growth factor receptor 3 (HER3) triggers multiple intracellular pathways resulting in tumor cell survival. This Phase 1 study assessed the safety, efficacy, and pharmacokinetics (PK)...
6.
Ferretti A, Kula T, Wang Y, Nguyen D, Weinheimer A, Dunlap G, et al.
Immunity
. 2020 Oct;
53(5):1095-1107.e3.
PMID: 33128877
Developing effective strategies to prevent or treat coronavirus disease 2019 (COVID-19) requires understanding the natural immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used an unbiased, genome-wide...
7.
Casaletto J, Geddie M, Abu-Yousif A, Masson K, Fulgham A, Boudot A, et al.
Proc Natl Acad Sci U S A
. 2019 Mar;
116(15):7533-7542.
PMID: 30898885
Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as amplification or receptor overexpression, has been implicated in driving...
8.
Schelker M, Feau S, Du J, Ranu N, Klipp E, MacBeath G, et al.
Nat Commun
. 2017 Dec;
8(1):2032.
PMID: 29230012
As interactions between the immune system and tumour cells are governed by a complex network of cell-cell interactions, knowing the specific immune cell composition of a solid tumour may be...
9.
Hass H, Masson K, Wohlgemuth S, Paragas V, Allen J, Sevecka M, et al.
NPJ Syst Biol Appl
. 2017 Sep;
3:27.
PMID: 28944080
Targeted therapies have shown significant patient benefit in about 5-10% of solid tumors that are addicted to a single oncogene. Here, we explore the idea of ligand addiction as a...
10.
Schoeberl B, Kudla A, Masson K, Kalra A, Curley M, Finn G, et al.
NPJ Syst Biol Appl
. 2017 Jul;
3:16034.
PMID: 28725482
The ErbB family of receptor tyrosine kinases comprises four members: epidermal growth factor receptor (EGFR/ErbB1), human EGFR 2 (HER2/ErbB2), ErbB3/HER3, and ErbB4/HER4. The first two members of this family, EGFR...